首页> 外文期刊>Arthritis research & therapy. >Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis
【24h】

Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis

机译:血浆补充因子h与ANCA相关血管炎患者的疾病活动有关

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Increasing evidences have demonstrated that activation of alternative complement pathway plays an important role in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The current study aimed to investigate the association of complement factor H (CFH), a key regulator of the alternative complement pathway, with the disease activity of AAV. Methods: Plasma CFH levels were measured in 82 patients with myeloperoxidase (MPO)-AAV in active stage. Of the 82 patients, plasma CFH levels of 27 patients were longitudinally measured. Serum anti-CFH autoantibodies were screened in AAV patients. Circulating complement activation profiles including C4d, Bb, C3a, C5a and soluble C5b-9 of AAV patients in active stage were further detected. Associations between plasma CFH levels and clinicopathological parameters as well as the prognosis were analyzed. Results: Plasma CFH levels were significantly lower in active AAV patients compared with AAV patients in remission and normal controls. Correlation analysis showed that plasma CFH levels inversely correlated with initial serum creatinine, Birmingham Vasculitis Activity Score (BVAS), proportion of total crescents and cellular crescents in renal specimens, and circulating levels of C3a, C5a and Sc5b-9, meanwhile positively correlated with estimated glomerular filtration rate (eGFR), hemoglobin levels and circulating levels of C3. Moreover, multivariate survival analysis revealed that plasma CFH levels were independently associated with composite outcome of death or end stage renal disease (ESRD) in AAV patients, after adjusting for age, gender, hemoglobin level and urinary protein (P = 0.03, HR 0.85, 95 % CI 0.73–0.98) or adjusting for age, gender, total crescents (%) and urinary protein (P = 0.03, HR 0.85, 95 % CI 0.73–0.98), while not as an independent predictor after adjusting for age, gender, serum creatinine and urinary protein (P = 0.57, HR 0.96, 95 % CI 0.83–1.11). Conclusion: In conclusion, plasma CFH levels are associated with disease activity, and, to some extent, associated with composite outcomes of patients with MPO-ANCA-associated vasculitis.
机译:介绍:增加证据表明,替代补体途径的激活在抗中性粒细胞细胞质抗体(ANCA) - 分配血管炎(AAV)的发病机制中起重要作用。目前的研究旨在探讨补体因子H(CFH),替代补体途径的关键调节因子H(CFH)的关联,AAV疾病活性。方法:在82例髓过氧化物酶(MPO)患者中测量血浆CFH水平-AAV在活性阶段。在82名患者中,血浆CFH水平为27例患者纵向测量。在AAV患者中筛选血清抗CFH自身抗体。进一步检测到包括C4D,BB,C3A,C5A和AAV患者在活性阶段的C4D,BB,C3A,C5A和可溶性C5B-9的循环补体曲线。分析了血浆CFH水平与临床病理学参数之间的关联以及预后。结果:活性AAV患者的血浆CFH水平显着降低,与AAV患者进行缓解和正常对照。相关分析表明,血浆CFH水平与初始血清肌酐,伯明翰血管炎活动评分(BVA),肾标本中的总印度支那和细胞三月的比例,以及C3A,C5A和SC5B-9的循环水平,同时与估计呈正相关肾小球过滤速率(EGFR),血红蛋白水平和C3的循环水平。此外,多变量存活分析表明,在调整年龄,性别,血红蛋白水平和尿蛋白后,血浆CFH水平与AAV患者的死亡或末期肾病(ESRD)的复合结果相关(ESRD)(P = 0.03,HR 0.85, 95%CI 0.73-0.98)或调整年龄,性别,总新月(%)和尿蛋白(P = 0.03,HR 0.85,95%CI 0.73-0.98),而不是在调整年龄,性别后作为独立预测因子。 ,血清肌酐和尿蛋白(p = 0.57,hr 0.96,95%ci 0.83-1.11)。结论:总之,血浆CFH水平与疾病活动有关,在一定程度上与MPO-ANCA相关血管炎患者的复合结果相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号